organ
transplant
therapi
choic
endstag
organ
failur
year
organ
transplant
worldwid
unexpect
transmiss
infect
donor
recipi
infrequ
data
exist
bear
directli
degre
risk
transmiss
donorderiv
infect
transplant
organ
might
come
donor
unknown
asymptomat
infect
could
contamin
procur
implant
transmiss
infect
facilit
viabl
cell
vascular
organ
moreov
immunosuppress
drug
use
prevent
immunolog
attack
graft
graft
reject
may
amplifi
risk
infect
carri
donor
organ
exampl
west
nile
viru
wnv
report
caus
invas
neurolog
infect
often
immunocompromis
organ
recipi
normal
immunocompromis
host
diminish
inflammatori
respons
sign
symptom
infect
reduc
incid
infect
often
underestim
report
suspect
document
donorderiv
transmiss
event
requir
usa
voluntari
mani
countri
unexpect
diseas
transmiss
occur
less
solid
organ
contrast
hepat
c
viru
hcv
human
immunodefici
viru
hiv
transmit
screen
blood
product
less
one
million
unit
screen
process
blood
product
allow
confirmatori
test
enabl
discard
potenti
contamin
blood
limit
suppli
organ
urgent
need
implant
preserv
organ
function
procur
deceas
donor
preclud
prolong
screen
process
discard
potenti
use
graft
data
avail
directli
assess
risk
diseas
transmiss
organ
transplant
studi
difficult
costli
perform
microbiolog
screen
potenti
organ
donor
improv
avail
new
assay
nucleic
acid
test
nat
advanc
antibodi
test
howev
avail
assay
profici
clinic
laboratori
well
nation
regul
govern
report
advers
event
donor
screen
vari
region
includ
part
south
america
africa
asia
lack
requir
report
advers
event
transplant
addit
organ
increasingli
share
across
intern
border
identif
cluster
infect
associ
organ
transplant
result
reassess
screen
process
organ
articl
review
major
risk
factor
organdonorderiv
transmiss
infect
opportun
reduc
incid
event
histor
transmiss
bacteri
infect
prevent
use
surgic
prophylaxi
antibacteri
therapi
given
around
time
transplant
surgeri
emerg
multidrug
antimicrobi
resist
mdr
bacteria
yeast
speci
howev
routin
prophylaxi
might
fail
prevent
transmiss
organ
present
donor
organ
bloodstream
time
increasingli
common
mdr
organ
includ
extendedspectrum
esbl
produc
enterobacteriacea
carbapenemresist
acinetobact
baumannii
crab
klebsiella
pneumonia
crkp
carbapenemresist
enterobacteriacea
cre
transmit
morbid
caus
pathogen
among
organ
recipi
among
possibl
risk
factor
donor
colon
mdr
organ
prolong
day
stay
intens
care
unit
critic
ill
requir
vasopressor
support
need
cardiopulmonari
unfortun
donor
hospit
day
suffici
acquir
mdr
clinic
experi
suggest
respiratorycolon
crkpposit
crabposit
organ
donor
may
consid
candid
donor
organ
lung
close
followup
recipi
mandatori
similarli
donor
posit
urin
cultur
crkp
crab
transplant
kidney
avoid
unless
infect
erad
risk
exist
unrecogn
bacteraemia
caus
organ
presenc
mdr
bacteraemia
transplant
organ
avoid
efficaci
appropri
antimicrobi
treatment
donor
organ
procur
basi
vitro
suscept
data
prevent
recipi
infect
known
gener
period
effect
therapi
also
consid
recipi
transplant
result
microbiolog
cultur
obtain
time
organ
donat
might
avail
implant
given
delay
organ
recipi
may
increas
risk
donorderiv
rapid
commun
complet
microbiolog
suscept
data
organ
procur
organ
clinic
centr
essenti
guid
manag
recipi
infect
may
recogn
donorderiv
may
resist
therapi
immunocompromis
host
potenti
contribut
organ
loss
exampl
mycot
aneurysm
graft
blood
vessel
death
thu
possibl
infect
identifi
fulli
treat
donor
decis
regard
use
organ
might
infect
antimicrobialresist
pathogen
must
made
individu
basi
potenti
organ
recipi
increasingli
travel
abroad
reduc
cost
wait
time
transplant
donor
screen
region
limit
countri
payment
organ
donat
legal
donor
may
tend
come
low
socioeconom
strata
endem
infect
tuberculosi
malaria
chaga
diseas
leishmaniasi
might
common
unpaid
deceas
donor
case
seri
turkey
canada
california
mani
renal
recipi
travel
abroad
organ
develop
sever
infect
often
requir
travel
organ
donor
socal
transplant
tourist
might
becom
colon
highli
resist
strain
superbug
includ
vancomycinresist
staphylococci
mdr
enterobacteriacea
among
newer
isol
carbapenemas
enzym
call
new
delhi
make
bacteria
resist
wide
rang
antimicrobi
agent
first
identifi
india
sinc
detect
resist
trait
compromis
efficaci
almost
antimicrobi
includ
carbapenem
therapeut
option
infect
type
resist
bacteria
larg
limit
colistin
tigecyclin
fosfomycin
although
carbapenemas
constitut
critic
medic
issu
infect
yet
report
transplant
set
highli
resist
strain
bacteria
thought
emerg
antimicrobi
pressur
hospit
anim
use
meat
consumpt
via
contamin
fruit
veget
farm
seafood
bacteria
observ
patient
travel
china
india
southeast
asia
middl
east
balkan
australia
knowledg
specif
infect
exist
region
provid
transplant
servic
might
guid
patient
evalu
transplant
tourist
might
also
provid
vector
transmiss
new
mdr
organ
medic
institut
consequ
horizont
transmiss
mdr
pathogen
patient
could
occur
could
lead
institutionwid
outbreak
infect
stringent
infect
control
measur
control
spread
mdr
organ
implement
whenev
resist
pathogen
recogn
risk
transmiss
hbv
infect
donor
illustr
potenti
organspecif
pathogen
transmiss
import
vaccin
transplant
popul
transmiss
hbv
common
absenc
prophylaxi
base
avail
data
liver
transplant
recipi
recent
review
rate
de
novo
hbv
dnh
infect
without
prophylaxi
patient
hbv
nonimmun
recipi
patient
previous
vaccin
individu
patient
isol
recipi
antihbcagposit
posit
antibodi
hbv
core
antigen
patient
natur
immun
experi
produc
seri
prevent
strategi
prevent
dnh
hbv
surfac
antigen
hbsag
neg
recipi
survey
reveal
indefinit
antivir
therapi
commonli
employ
lamivudin
prefer
antivir
agent
antivir
variabl
supplement
hbv
hyperimmun
globulin
hbig
although
entecavir
tenofovir
supplant
lamivudin
treatment
chronic
hbv
infect
often
prophylaxi
liver
transplant
recipi
antihbcagposit
donor
new
studi
use
markov
model
demonstr
lamivudin
remain
costeffect
option
prevent
dnh
context
antihbcagposit
heart
kidney
transplant
recipi
limit
avail
data
suggest
risk
hbv
transmiss
use
organ
antihbcagposit
donor
low
without
posttranspl
antivir
avail
studi
often
limit
absenc
baselin
data
serolog
statu
presenc
antihb
hbsag
immunosuppress
regimen
donor
recipi
may
affect
transmiss
risk
earli
studi
heart
transplant
recipi
without
prophylaxi
reveal
hbv
transmiss
patient
like
vaccin
use
donor
heart
consid
safe
may
help
augment
avail
donor
interest
hbv
seroposit
donor
recipi
may
associ
increas
risk
cardiac
allograft
risk
transmiss
hbv
antihbcagposit
hbsagneg
donor
hbvnaiv
kidney
recipi
vari
definit
transmiss
highli
variabl
includ
acquisit
antihbsag
antihbcag
studi
requir
acquisit
hbsag
detect
hbv
dna
case
definit
risk
transmiss
influenc
recipi
hbv
immun
possibl
review
nine
studi
evalu
hbsagneg
recipi
kidney
antihbcagposit
donor
new
hbv
serolog
marker
observ
patient
rate
hbsag
acquisit
four
patient
evid
symptomat
studi
explor
influenc
recipi
antihbsag
statu
use
prophylact
therapi
patient
graft
outcom
wors
among
patient
hbsag
acquisit
evid
antihbsag
antihbcag
seroconvers
given
donor
organ
shortag
temptat
stretch
limit
donat
almost
irresist
unresolv
issu
includ
optim
durat
therapi
donor
bacteraemia
tuberculosi
mening
enceph
unknown
aetiolog
optim
prophylaxi
organ
donor
infect
hbv
hcv
human
herpesviru
human
tcell
lymphotrop
viru
htlv
organ
use
infect
donor
microbiolog
followup
recipi
essenti
basi
risk
factor
identifi
donor
retest
recipi
increas
risk
donor
organ
mandat
usa
elsewher
baselin
month
month
posttransplant
hiv
hcv
hbv
recommend
syphili
expert
also
recommend
long
period
monitor
month
storag
sampl
donor
recipi
blood
plasma
cell
futur
test
nation
guidelin
need
use
organ
donor
known
unexpect
transmiss
donorderiv
infect
estim
occur
less
solid
organ
transplant
cluster
infect
includ
tuberculosi
fungi
herp
simplex
viru
hsv
lcmv
rabi
viru
cruzi
microsporidiosi
hiv
hcv
found
multipl
recipi
receiv
organ
singl
donor
box
infect
often
caus
pathogen
may
amplifi
immunosuppress
host
asymptomat
mask
normal
organ
donor
clinic
syndrom
trauma
stroke
individu
transmiss
event
might
recogn
unless
clinic
manifest
develop
exampl
donorderiv
chronic
hepat
e
viru
infect
transmiss
identifi
immunosuppress
solid
organ
transplant
recipi
evalu
clinic
hepat
europ
absenc
system
autom
detect
report
posttransplant
infect
among
clinic
centr
procur
organ
recognit
event
depend
clinic
suspicion
transplant
team
confirm
donorderivedinfect
transmiss
event
organ
recipi
notabl
face
unusu
pathogen
requir
special
clinic
laboratori
epidemiolog
investig
public
health
author
intern
consensu
definit
donorderiv
infect
test
donor
potenti
pathogen
imposs
assay
organ
exist
requir
would
substanti
delay
transplant
clinic
recognit
unusu
clinic
syndrom
cluster
organ
recipi
singl
donor
usa
australia
result
develop
new
nat
assay
lcmv
relat
virus
applic
nonspecif
highthroughput
sequenc
tool
capac
detect
unusu
nucleic
acid
sequenc
blood
diagnost
new
arenaviru
cluster
fatal
transplantassoci
infect
standard
microbiolog
techniqu
current
reactiv
statu
potenti
donor
contraind
organ
donat
european
countri
recent
legal
hivposit
recipi
usa
three
hivinfect
donor
use
inadvert
falseneg
test
erron
report
result
transmiss
viru
uninfect
although
diseas
transmiss
involv
deceas
donor
recent
unexpect
transmiss
hiv
hcv
shown
recipi
organ
live
donor
may
also
donorderiv
hiv
transmiss
gener
bad
outcom
howev
three
patient
receiv
organ
hivinfect
donor
italian
cluster
includ
two
kidney
transplant
recipi
still
aliv
undetect
hivrna
good
tcell
count
function
graft
year
transplant
p
grossi
unpublish
work
transmiss
donorderiv
htlv
report
natur
histori
transmiss
donor
recipi
unknown
given
suboptim
screen
platform
lack
longterm
followup
definit
case
transmiss
solidorgan
donorderiv
diseas
emerg
seroneg
recipi
two
kidney
one
liver
develop
myelopathi
within
year
transplant
viru
ident
sequenc
donor
asymptomat
congenit
infect
donorderiv
death
report
basi
data
countri
low
preval
europ
usa
owe
current
shortag
donor
organ
assess
everi
donor
longer
consid
essenti
current
screen
method
differenti
infect
falseposit
screen
assay
util
screen
uncertain
absenc
longterm
followup
data
screen
recommend
endem
area
endem
popul
past
sever
year
emerg
pathogen
wnv
identifi
sourc
donorderiv
infect
transmiss
wnv
organ
transplant
describ
four
recipi
organ
singl
rout
transmiss
rare
screen
organ
donor
wnv
routin
remain
controversi
long
turnaround
time
result
unproven
test
perform
limit
test
avail
made
routin
test
impract
furthermor
transmiss
wnv
occur
absenc
detect
viraemia
seroconvers
organ
low
viral
load
blood
short
durat
viraemia
normal
individu
present
major
problem
nucleic
acid
amplif
test
kidney
may
site
prolong
wnv
replic
shed
anim
thu
urin
sampl
could
appropri
blood
wnv
test
organ
donor
prospect
studi
need
verifi
util
routin
wnv
test
urin
blood
organ
donor
rabi
caus
acut
enceph
nearli
uniformli
fatal
unvaccin
host
although
viru
present
anim
reservoir
infect
human
rare
usa
europ
two
cluster
rabi
viru
transmiss
organ
transplant
attribut
bat
canin
rabi
viru
variant
nonvaccin
recipi
develop
initi
unrecogn
rabi
symptom
within
week
transplant
observ
suggest
high
rabi
infect
rate
abbrevi
incub
period
unvaccin
immunosuppress
recipi
solid
similar
issu
diseas
recognit
occur
recent
cluster
primari
amoeb
meningoenceph
pam
caus
freeliv
amoeba
three
transplantassoci
cluster
enceph
caus
amoeba
balamuthia
mandrillari
demonstr
risk
associ
solid
organ
transplant
donor
person
hispan
ethnic
may
disproportion
unrecogn
skin
lesion
may
preced
enceph
month
year
pool
foreign
donor
increas
unusu
infect
malaria
tuberculosi
chaga
diseas
strongyloidiasi
repres
grow
threat
transplant
recipi
usa
endem
fungi
histoplasma
midwest
coccidioid
southwest
region
repres
notabl
risk
routin
prophylaxi
appli
mani
recipi
notabl
lung
transplant
differenti
diagnosi
fever
enceph
within
first
week
transplant
includ
donorderiv
pathogen
serolog
test
infect
highli
effect
donor
screen
howev
seroconvers
requir
elabor
antibodi
specif
pathogen
could
delay
sever
week
infecti
exposur
window
period
like
result
falseneg
test
result
could
result
inadvert
transmiss
infect
figur
nat
assay
detect
viral
nucleic
acid
directli
follow
signal
amplif
greater
sensit
specif
serolog
test
result
window
period
hiv
detect
use
nat
reduc
day
use
antibodi
screen
minimum
day
reduct
potenti
recipi
exposur
use
nat
instead
serolog
figur
similar
reduct
window
period
observ
hcv
hbv
detect
tabl
residu
risk
infecti
transmiss
face
falseneg
serolog
nat
test
estim
low
hiv
hcv
tabl
howev
outbreak
wnv
falseneg
result
detect
serolog
nat
assay
suggest
dual
test
benefici
untreat
infect
qualiti
laboratori
test
essenti
compon
safeti
paradigm
transplant
depend
assay
perform
qualiti
specimen
test
laboratori
assay
may
lack
requir
sensit
specif
may
improperli
perform
specimen
may
becom
degrad
contamin
handl
data
may
erron
record
commun
intern
qualiti
control
laboratori
procedur
essenti
qualiti
perform
characterist
limit
assay
must
track
organ
procur
organ
cost
infrastructur
requir
need
assur
mainten
profici
may
dictat
use
region
valid
central
test
laboratori
organ
donor
screen
assay
data
may
compar
laboratori
use
differ
commerci
test
laboratorydevelop
socal
home
brew
reagent
new
test
develop
face
chang
epidemiolog
may
lack
valid
larg
clinic
popul
falseposit
falseneg
test
could
occur
result
valid
new
assay
difficult
valid
studi
deceas
live
donor
popul
rare
pathogen
rabi
lcmv
almost
imposs
perform
introduct
new
assay
screen
panel
requir
consider
whether
assay
valid
perform
relev
clinic
laboratori
exampl
even
endem
region
introduct
serolog
test
hepat
e
problemat
owe
sensit
issu
difficulti
perform
reliabl
assay
may
use
alloc
discard
organ
test
lifethreaten
untreat
diseas
requir
assay
optim
sensit
thu
confirmatori
test
intern
control
must
employ
detect
falseposit
falseneg
test
broad
array
organ
may
transmit
live
cell
transplant
organ
donor
screen
improv
avail
sensit
microbiolog
assay
target
common
pathogen
incid
infecti
diseas
result
donorderiv
infect
low
although
exact
data
lack
infect
probabl
detect
immunocompromis
recipi
develop
diseas
unusu
sever
infect
low
nativ
virul
sentinel
new
unusu
infect
commun
patient
popul
especi
affect
exampl
inadvert
transmiss
hcv
wnv
chaga
diseas
absenc
highli
sensit
test
key
element
detect
donorderiv
infect
remain
suspicion
part
clinician
care
organ
recipi
present
donorderiv
infect
often
obscur
includ
unexplain
cultureneg
enceph
weak
fever
thrombocytopenia
lymphocytosi
erythema
surgic
incis
graft
dysfunct
organ
procur
organ
publichealth
author
engag
evalu
incid
microbiolog
identif
donorderiv
pathogen
transplant
recipi
import
enabl
appropri
therapi
affect
individu
recogn
outbreak
infecti
diseas
immunocompromis
host
pathogen
affect
broader
popul
test
protocol
must
adapt
known
chang
epidemiolog
diseas
incorpor
new
technolog
microbiolog
screen
screen
technolog
may
incorpor
new
highthroughput
genet
sequenc
new
sequenc
circul
multiplex
assay
target
mani
specif
pathogen
simultan
singl
identif
potenti
pathogen
organ
implant
also
import
implic
need
rapid
commun
microbiolog
data
clinic
suspicion
clinic
laboratori
clinic
centr
procur
organ
publichealth
author
prospect
research
requir
clarifi
incid
diseas
transmiss
optim
panel
microbiolog
assay
donor
screen
improv
coordin
inform
must
facilit
publichealth
author
clinic
centr
patient
tissu
organ
procur
group
standard
investig
report
terminolog
data
share
potenti
transmiss
event
enhanc
safeti
organ
transplant
worldwid
obtain
paper
use
develop
usph
guidelin
origin
articl
publish
index
medlin
pubm
base
search
term
donorderiv
transmiss
organ
transplant
infect
alon
combin
articl
identifi
fulltext
paper
also
search
refer
list
identifi
articl
relev
paper
